Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma

Analysis of TCGA data

Eunyoung Kim, Sohee Jung, Won Seo Park, Joon Hyop Lee, Ru Mi Shin, Suung Chul Heo, Eun Kyung Choe, Jae Hyun Lee, Kwangsoo Kim, Young Jun Chai

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Upregulation of SLC2A genes that encode glucose transporter (GLUT) protein is associated with poor prognosis in many cancers. In colorectal cancer, studies reporting the association between overexpression of GLUT and poor clinical outcomes were flawed by small sample sizes or subjective interpretation of immunohistochemical staining. Here, we analyzed mRNA expressions in all 14 SLC2A genes and evaluated the association with prognosis in colorectal cancer using data from the Cancer Genome Atlas (TCGA) database. Methods: In the present study, we analyzed the expression of SLC2A genes in colorectal cancer and their association with prognosis using data obtained from the TCGA for the discovery sample, and a dataset from the Gene Expression Omnibus for the validation sample. Results: SLC2A3 was significantly associated with overall survival (OS) and disease-free survival (DFS) in both the discovery sample (345 patients) and validation sample (501 patients). High SLC2A3 expression resulted in shorter OS and DFS. In multivariate analyses, high SLC2A3 levels predicted unfavorable OS (adjusted HR 1.95, 95% CI 1.22-3.11; P = 0.005) and were associated with poor DFS (adjusted HR 1.85, 95% CI 1.10-3.12; P = 0.02). Similar results were found in the discovery set. Conclusion: Upregulation of the SLC2A3 genes is associated with decreased OS and DFS in colorectal cancer patients. Therefore, assessment of SLC2A3 gene expression may useful for predicting prognosis in these patients.

Original languageEnglish
Article number302
JournalBMC Cancer
Volume19
Issue number1
DOIs
StatePublished - 3 Apr 2019

Fingerprint

Atlases
Disease-Free Survival
Colorectal Neoplasms
Up-Regulation
Genome
Survival
Facilitative Glucose Transport Proteins
Gene Expression
Genes
Neoplasms
Sample Size
Multivariate Analysis
Databases
Staining and Labeling
Messenger RNA
Proteins

Keywords

  • Colorectal cancer
  • Glucose transporter (GLUT)
  • Prognosis
  • Solute carrier 2A (SLC2A)
  • The cancer genome atlas (TCGA)

Cite this

Kim, Eunyoung ; Jung, Sohee ; Park, Won Seo ; Lee, Joon Hyop ; Shin, Ru Mi ; Heo, Suung Chul ; Choe, Eun Kyung ; Lee, Jae Hyun ; Kim, Kwangsoo ; Chai, Young Jun. / Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma : Analysis of TCGA data. In: BMC Cancer. 2019 ; Vol. 19, No. 1.
@article{7e0a3f9e26814905a7db3b53f3869870,
title = "Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma: Analysis of TCGA data",
abstract = "Background: Upregulation of SLC2A genes that encode glucose transporter (GLUT) protein is associated with poor prognosis in many cancers. In colorectal cancer, studies reporting the association between overexpression of GLUT and poor clinical outcomes were flawed by small sample sizes or subjective interpretation of immunohistochemical staining. Here, we analyzed mRNA expressions in all 14 SLC2A genes and evaluated the association with prognosis in colorectal cancer using data from the Cancer Genome Atlas (TCGA) database. Methods: In the present study, we analyzed the expression of SLC2A genes in colorectal cancer and their association with prognosis using data obtained from the TCGA for the discovery sample, and a dataset from the Gene Expression Omnibus for the validation sample. Results: SLC2A3 was significantly associated with overall survival (OS) and disease-free survival (DFS) in both the discovery sample (345 patients) and validation sample (501 patients). High SLC2A3 expression resulted in shorter OS and DFS. In multivariate analyses, high SLC2A3 levels predicted unfavorable OS (adjusted HR 1.95, 95{\%} CI 1.22-3.11; P = 0.005) and were associated with poor DFS (adjusted HR 1.85, 95{\%} CI 1.10-3.12; P = 0.02). Similar results were found in the discovery set. Conclusion: Upregulation of the SLC2A3 genes is associated with decreased OS and DFS in colorectal cancer patients. Therefore, assessment of SLC2A3 gene expression may useful for predicting prognosis in these patients.",
keywords = "Colorectal cancer, Glucose transporter (GLUT), Prognosis, Solute carrier 2A (SLC2A), The cancer genome atlas (TCGA)",
author = "Eunyoung Kim and Sohee Jung and Park, {Won Seo} and Lee, {Joon Hyop} and Shin, {Ru Mi} and Heo, {Suung Chul} and Choe, {Eun Kyung} and Lee, {Jae Hyun} and Kwangsoo Kim and Chai, {Young Jun}",
year = "2019",
month = "4",
day = "3",
doi = "10.1186/s12885-019-5475-x",
language = "English",
volume = "19",
journal = "BMC cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
number = "1",

}

Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma : Analysis of TCGA data. / Kim, Eunyoung; Jung, Sohee; Park, Won Seo; Lee, Joon Hyop; Shin, Ru Mi; Heo, Suung Chul; Choe, Eun Kyung; Lee, Jae Hyun; Kim, Kwangsoo; Chai, Young Jun.

In: BMC Cancer, Vol. 19, No. 1, 302, 03.04.2019.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma

T2 - Analysis of TCGA data

AU - Kim, Eunyoung

AU - Jung, Sohee

AU - Park, Won Seo

AU - Lee, Joon Hyop

AU - Shin, Ru Mi

AU - Heo, Suung Chul

AU - Choe, Eun Kyung

AU - Lee, Jae Hyun

AU - Kim, Kwangsoo

AU - Chai, Young Jun

PY - 2019/4/3

Y1 - 2019/4/3

N2 - Background: Upregulation of SLC2A genes that encode glucose transporter (GLUT) protein is associated with poor prognosis in many cancers. In colorectal cancer, studies reporting the association between overexpression of GLUT and poor clinical outcomes were flawed by small sample sizes or subjective interpretation of immunohistochemical staining. Here, we analyzed mRNA expressions in all 14 SLC2A genes and evaluated the association with prognosis in colorectal cancer using data from the Cancer Genome Atlas (TCGA) database. Methods: In the present study, we analyzed the expression of SLC2A genes in colorectal cancer and their association with prognosis using data obtained from the TCGA for the discovery sample, and a dataset from the Gene Expression Omnibus for the validation sample. Results: SLC2A3 was significantly associated with overall survival (OS) and disease-free survival (DFS) in both the discovery sample (345 patients) and validation sample (501 patients). High SLC2A3 expression resulted in shorter OS and DFS. In multivariate analyses, high SLC2A3 levels predicted unfavorable OS (adjusted HR 1.95, 95% CI 1.22-3.11; P = 0.005) and were associated with poor DFS (adjusted HR 1.85, 95% CI 1.10-3.12; P = 0.02). Similar results were found in the discovery set. Conclusion: Upregulation of the SLC2A3 genes is associated with decreased OS and DFS in colorectal cancer patients. Therefore, assessment of SLC2A3 gene expression may useful for predicting prognosis in these patients.

AB - Background: Upregulation of SLC2A genes that encode glucose transporter (GLUT) protein is associated with poor prognosis in many cancers. In colorectal cancer, studies reporting the association between overexpression of GLUT and poor clinical outcomes were flawed by small sample sizes or subjective interpretation of immunohistochemical staining. Here, we analyzed mRNA expressions in all 14 SLC2A genes and evaluated the association with prognosis in colorectal cancer using data from the Cancer Genome Atlas (TCGA) database. Methods: In the present study, we analyzed the expression of SLC2A genes in colorectal cancer and their association with prognosis using data obtained from the TCGA for the discovery sample, and a dataset from the Gene Expression Omnibus for the validation sample. Results: SLC2A3 was significantly associated with overall survival (OS) and disease-free survival (DFS) in both the discovery sample (345 patients) and validation sample (501 patients). High SLC2A3 expression resulted in shorter OS and DFS. In multivariate analyses, high SLC2A3 levels predicted unfavorable OS (adjusted HR 1.95, 95% CI 1.22-3.11; P = 0.005) and were associated with poor DFS (adjusted HR 1.85, 95% CI 1.10-3.12; P = 0.02). Similar results were found in the discovery set. Conclusion: Upregulation of the SLC2A3 genes is associated with decreased OS and DFS in colorectal cancer patients. Therefore, assessment of SLC2A3 gene expression may useful for predicting prognosis in these patients.

KW - Colorectal cancer

KW - Glucose transporter (GLUT)

KW - Prognosis

KW - Solute carrier 2A (SLC2A)

KW - The cancer genome atlas (TCGA)

UR - http://www.scopus.com/inward/record.url?scp=85064068213&partnerID=8YFLogxK

U2 - 10.1186/s12885-019-5475-x

DO - 10.1186/s12885-019-5475-x

M3 - Article

VL - 19

JO - BMC cancer

JF - BMC cancer

SN - 1471-2407

IS - 1

M1 - 302

ER -